Daniella Abi Kheir

Daniella Abi Kheir, a critical care pharmacy resident and SGLT2 inhibitor expert, joins host Jimmy Pruitt to explore the revolutionary potential of these drugs in ICU settings. They discuss the DEFENDER trial, unveiling how SGLT2 inhibitors may prevent renal replacement therapy and enhance outcomes in sepsis. The duo addresses safety concerns, such as DKA, and emphasizes the need for healthcare professionals to rethink these agents' roles. Additionally, they highlight the multifaceted benefits of SGLT2 inhibitors beyond diabetes management.